Close Menu
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India

November 21, 2026

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026

Kingston Debuts at Embedded World India, Deepening Its B2B Push in India’s Enterprise and Industrial Markets

November 21, 2026
Facebook X (Twitter) Instagram
Trending
  • The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India
  • ‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam
  • Kingston Debuts at Embedded World India, Deepening Its B2B Push in India’s Enterprise and Industrial Markets
  • Heart and Lung Transplant Recipients Share Stories of a New Life at KIMS Patient Meet in Indore
  • Rahul Gupta: 10 Years of Selfless Service, Compassion and Humanity
  • Vijay Arora Announces Sataack 50, a Professional Tennis-Ball Cricket League for Men and Women
  • HRH Next Services Limited Reports H1 FY27 Results
  • World Record Holder Vineet Singh Hukmani Releases First Global Mahjong Anthem From India.
The Startup StoryThe Startup Story
  • Business
  • Lifestyle
  • National
  • Education
  • Health
  • Technology
  • World
The Startup StoryThe Startup Story
Home»Press Release»Concept Medical Enrolls First Patient in MAGICAL-SV IDE Trial, Expands Coronary Program Globally
Press Release

Concept Medical Enrolls First Patient in MAGICAL-SV IDE Trial, Expands Coronary Program Globally

Arjun SinghBy Arjun SinghAugust 4, 2025No Comments
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Tampa (Florida) [USA], August 4: Concept Medical Inc., a global pioneer in drug-delivery technologies, today announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first enrollment marks a major milestone in the company’s mission to revolutionize coronary artery disease (CAD) treatment and expands Concept Medical’s clinical program into the United States and Europe.

The first patient was enrolled at Mount Sinai Hospital in New York by Dr. Samin Sharma, Director of Interventional Cardiology, marking a crucial step in advancing treatment options for patients with small-vessel coronary artery disease.

“Today marks a great feat for us and for the MAGICAL-SV trial,” said Dr. Samin Sharma. “My team at Mount Sinai is privileged to be the first to begin this study. This is a proud moment for all of us, especially knowing what the trial signifies and aims to achieve by evaluating MagicTouchas a potential alternative for treating small vessels in the U.S.”

This initial U.S. enrollment follows the FDA’s IDE approval of Concept Medical’s MagicTouch SCB and boosts the company’s broader coronary clinical program. Concept Medical is now actively enrolling in three IDE trials concurrently in the U.S., spanning across coronary and peripheral interventions and underscoring its commitment to bringing innovative therapies to patients worldwide.

MAGICAL-SV is a prospective, multicenter, single-blind randomized trial (2:1 randomization) comparing Concept Medical’s MagicTouch sirolimus-coated balloon to drug-eluting stents (Everolimus eluting stents [EES] or Zotarolimus eluting stents [ZES]) for the treatment of small coronary artery lesions. Randomization is stratified by study site and presence of medically-treated diabetes mellitus status. The trial will enroll 1,605 patients across the U.S. and Europe, to evaluate the primary endpoint of target lesion failure (TLF) at 12 months.

The MAGICAL-SV trial is led by an international team of renowned cardiologists, Dr. Martin B. Leon (USA) serves as Study Chair, with principal investigators (PI) Dr. Azeem Latib (USA), Dr. Ajay Kirtane (USA), and Prof. Antonio Colombo (Europe).

Dr. Azeem Latib, a U.S. PI for MAGICAL-SV, noted, “The first U.S. patient enrollment in the MAGICAL-SV study marks an exciting step forward in building robust evidence for sirolimus-coated balloon technology in the treatment of small-vessel coronary disease. As we explore metal-free PCI strategies, this study brings renewed hope for safer, more effective options for our patients.”

Prof. Antonio Colombo, who leads the European arm of the study, added, “Starting small and going big! MAGICAL-SV represents an important step in building evidence for sirolimus-coated balloons.”

This milestone embodies a “leave nothing behind” philosophy in coronary interventions, treating arterial blockages without permanent implants and addressing the limitations of metallic stents in small vessels. Dr. Martin B. Leon, the Study Chair, emphasized the significance of evaluating a no-stent strategy through this trial: “The initiation of the MAGICAL-SV trial marks an important step in evaluating sirolimus-coated balloon therapy for small coronary vessels. By addressing key limitations of stenting in this complex anatomy, the study aims to generate strong comparative data versus DES. The results could inform future treatment strategies in the U.S. and Europe, offering clinicians a potential alternative for managing small-vessel disease.”

With this pioneering trial, MAGICAL-SV is expected to yield compelling clinical evidence in support of sirolimus-coated balloon therapy. The outcomes will also support Concept Medical’s Pre-Market Approval (PMA) application for the MagicTouch SCB in small-vessel indication, potentially transforming the standard of care in coronary artery disease.

Dr. Manish Doshi, Founder and Managing Director of Concept Medical, said, “At Concept Medical, our unwavering commitment to innovation and patient care drives us to push the boundaries of what is possible in vascular interventions. The initiation of MAGICAL-SV reinforces our dedication to delivering next-generation, evidence-based solutions to clinicians and patients across the globe. Our ultimate goal is to transform the current standard of care and provide better outcomes and quality of life for patients affected by CAD.”

About MagicTouch SCB

MagicTouch SCB is Concept Medical’s sirolimus-coated balloon platform, developed with proprietary Nanoluté technology to deliver sub-micron particles of sirolimus in a biocompatible carrier for deep arterial wall penetration. The device has received CE Mark approval in Europe and a Breakthrough Device designation from the U.S. FDA for small coronary vessels and in-stent restenosis.

About Concept Medical

Concept Medical Inc., headquartered in Tampa, Florida, is a global leader in cutting-edge drug-delivery technologies for cardiovascular interventions. The company is dedicated to improving patient care through research and development of novel drug-delivery platforms engineered to precisely deliver therapeutic agents to diseased vascular tissue. Concept Medical’s MagicTouch family of sirolimus-coated balloons is the world’s first and most widely used SCB technology, recognized for its versatility, safety and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have treated over one million patients worldwide, setting a new benchmark in vascular therapy.

For media inquiries, please contact: pr@conceptmedical.com

PR press-release
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
Arjun Singh
  • Website

Related Posts

Best Crypto Presale 2026: AlphaPepe Triggers Buying Surge with Up to 200% Bonus Drop as Bitcoin Eyes $100K

September 1, 2026

Resilience Actions, a Re Sustainability Initiative, Launches ECOHUB.IN to Power India’s Climate and Circular Economy Innovation Ecosystem

July 3, 2026

Social Activist Shanaya Sharma Honored with Prestigious Nari Astitva Award 2026

March 10, 2026

Comments are closed.

Top Posts

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020

Make your own inhouse library and learn

February 22, 2020
Don't Miss
Business

The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India

By Arjun SinghNovember 21, 2026

The Indian rug brand pairs online shopping with personal consultations, home trials and bespoke design…

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026

Kingston Debuts at Embedded World India, Deepening Its B2B Push in India’s Enterprise and Industrial Markets

November 21, 2026

Heart and Lung Transplant Recipients Share Stories of a New Life at KIMS Patient Meet in Indore

November 21, 2026
Most Popular

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026

Can we guess, how much she is happy?

February 22, 2020

When sunrise and the day begins.

February 22, 2020
Categories
  • Business
  • Business News
  • Education
  • Entertainment
  • Finance
  • Health
  • Lifestyle
  • National
  • Press Release
  • Sports
  • Technology
  • Uncategorized
  • World
Our Picks

The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India

November 21, 2026

‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam

November 21, 2026

Kingston Debuts at Embedded World India, Deepening Its B2B Push in India’s Enterprise and Industrial Markets

November 21, 2026

Type above and press Enter to search. Press Esc to cancel.